Scapa Healthcare has purchased Acelity’s Systagenix manufacturing facility situated in Gargrave, UK.
The transaction included warehouse facilities, research and development (R&D), regulatory support activities, as well as sterilisation operations.
Scapa Healthcare will manufacture Acelity’s KCI advanced wound dressings portfolio at the Gargrave site.
Based in the UK, Scapa Healthcare is a manufacturer of advanced wound care, consumer wellness and adhesive-based products for the healthcare and industrial sectors, while Acelity is a US-based private medical device company.
The acquisition expands Scapa’s global presence and strengthens its manufacturing capabilities.
BioLargo will acquire Scion Solutions’ breakthrough stem cell therapy technology, SkinDisc, which uses a patient’s bone marrow and plasma to heal chronic wounds.
The product will be marketed by BioLargo’s subsidiary, Clyra Medical Technologies.
The purchase is subject to the raising of a minimum capital of $1m in 120 days by Clyra. Parties may terminate the transaction if the amount is not raised.
The terms of agreement entitle Scion to receive 20% of Clyra’s common stock, 7.14 million of BioLargo common stock shares, as well as a promissory note for a principal amount of $1.25m.
Based in the US, BioLargo is an innovative platform technology developer, while Scion Solutions, also based in the US, is a medical device company.
Checkpoint Surgical has raised $8.8m in a preferred series capital round from Mutual Capital Partners, a venture fund based in the US.
The funding round also saw the participation of equity firm First Analysis, venture fund JumpStart NEXT Fund, and other individual investors.
Checkpoint Surgical plans to enhance its sales and marketing resources, bolster its executive team, and explore new products and market opportunities for nerve regeneration and neuroma pain.
All the entities involved in the transaction are based in the US.
US-based Owlstone Medical has raised $35m from Horizons Ventures, Ventura Capital, and Foxconn Technologies Group.
The transaction brings the total funds raised by the company to $73m, including the previously announced $15m.
Owlstone plans to use the funds towards the commercialisation of its Breath Biopsy kits and to further invest in its technology platform for additional high-value applications.